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Background
Compounds currently used for the treatment of HIV-1
infections are targeted to viral proteins. However, the
high intrinsic mutation and replication rates of HIV-1 led
to the emergence of drug resistant strains with a conse-
quent therapeutic failure. On this basis, cellular cofactors
represent attractive new targets for HIV-1 chemotherapy,
since targeting a cellular factor that is required for viral
replication should help to overcome the problem of viral
resistance. We aimed to develop through rational design
a series of non-nucleosidic inhibitors of the HIV-1 cellu-
l a rc o f a c t o rD D X 3a n ds h o wt h a tt h e yc a nb eu s e dt o
block viral proliferation.
Methods
The X-ray crystallographic structure of human helicase
DDX3 in complex with AMP has been used to generate
a structure-based pharmacophoric model to be inserted
in a computational protocol for the identification of
small inhibitors of the ATPase activity of DDX3. Next,
the pharmacophore was used as the three-dimensional
query of a virtual screening approach to filter databases
of commercially available compounds in order to iden-
tify chemical scaffolds with putative affinity toward the
DDX3 ATP binding site. Positive hits were tested in
antienzymatic and antiviral assays. An iterative process
of synthesis, testing and optimization was used to derive
lead compounds.
Results
One positive hit was identified in the first virtual screen-
ing with an IC50 against the enzymatic activity of DDX3
of 5 μM. The mechanism of action was found uncompe-
titive with respect to ATP and dependent on the multi-
meric state of the enzyme and several derivatives have
been synthesized. Among those, some compounds
showed nanomolar potencies against the enzymatic
activity of DDX3 and micromolar potencies against
HIV-1 replication in PBMCs, with no detectable
toxicities.
Discussion
We report the identification of the first non-nucleosidic
compounds suppressing HIV-1 replication by targeting a
cellular enzyme. Our results provide a proof-of-principle
for the feasibility of blocking HIV-1 infection by render-
ing the host cell environment less favourable for the
virus. This approach may potentially overcome the pro-
blem of drug resistance related to drugs targeting viral
proteins
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